These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23719348)

  • 1. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
    Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S
    AIDS; 2013 Mar; 27(5):761-8. PubMed ID: 23719348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
    Hien H; Meda N; Diagbouga S; Zoure E; Yaméogo S; Tamboura H; Somé J; Ouiminga A; Rouet F; Drabo A; Hien A; Nicolas J; Chappuy H; Van de Perre P; Msellati P; Nacro B
    Afr Health Sci; 2013 Jun; 13(2):287-94. PubMed ID: 24235926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
    Barro M; Some J; Foulongne V; Diasso Y; Zouré E; Hien H; François R; Michel S; Drabo A; Tamboura H; Ouiminga A; Diagbouga S; Hien A; Yaméogo S; Van De Perre P; Nacro B; Msellati P
    J Acquir Immune Defic Syndr; 2011 Jul; 57 Suppl 1():S44-9. PubMed ID: 21857286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Bouazza N; Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Van De Perre P; Tréluyer JM; Msellati P; Urien S
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3280-6. PubMed ID: 20516271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
    N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
    N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
    Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    Int J Immunopathol Pharmacol; 2012; 25(1):247-58. PubMed ID: 22507337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.
    Nacro B; Zoure E; Hien H; Tamboura H; Rouet F; Ouiminga A; Drabo A; Yameogo S; Hien A; Peyriere H; Mathieu O; Hirt D; Treluyer JM; Nicolas J; Foulongne V; Segondy M; van de Perre P; Diagbouga S; Msellati P
    Bull World Health Organ; 2011 Jun; 89(6):451-8. PubMed ID: 21673861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
    Molina JM; Peytavin G; Perusat S; Lascoux-Combes C; Sereni D; Rozenbaum W; Chene G
    HIV Med; 2004 Mar; 5(2):99-104. PubMed ID: 15012649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
    Bouazza N; Cressey TR; Foissac F; Bienczak A; Denti P; McIlleron H; Burger D; Penazzato M; Lallemant M; Capparelli EV; Treluyer JM; Urien S
    J Antimicrob Chemother; 2017 Feb; 72(2):490-495. PubMed ID: 27798221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
    Pavia-Ruz N; Rossouw M; Sáez-Llorens X; Bunupuradah T; Taylor M; Yang R; Sevinsky H; Krystal M; Lataillade M; Seekins D; Biguenet S
    Pediatr Infect Dis J; 2015 Dec; 34(12):1355-60. PubMed ID: 26379163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
    Variava E; Sigauke FR; Norman J; Rakgokong M; Muchichwa P; Mochan A; Maartens G; Martinson NA
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):577-579. PubMed ID: 28520619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
    Neely M; Louie S; Xu J; Anthony P; Thuvamontolrat K; Mordwinkin N; Kovacs A
    J Clin Pharmacol; 2015 Jul; 55(7):798-808. PubMed ID: 25683232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
    Palombi L; Pirillo MF; Marchei E; Jere H; Sagno JB; Luhanga R; Floridia M; Andreotti M; Galluzzo CM; Pichini S; Mwenda R; Mancinelli S; Marazzi MC; Vella S; Liotta G; Giuliano M
    J Antimicrob Chemother; 2016 Apr; 71(4):1027-30. PubMed ID: 26679247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
    Fillekes Q; Natukunda E; Balungi J; Kendall L; Bwakura-Dangarembizi M; Keishanyu R; Ferrier A; Lutakome J; Gibb DM; Burger DM; Walker AS;
    J Acquir Immune Defic Syndr; 2011 Dec; 58(4):392-8. PubMed ID: 21926634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
    Sungi SS; Ngaimisi E; Ulenga N; Sasi P; Mugusi S
    BMC Pharmacol Toxicol; 2018 Oct; 19(1):66. PubMed ID: 30352627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.
    Bruno R; Regazzi MB; Ciappina V; Villani P; Sacchi P; Montagna M; Panebianco R; Filice G
    Clin Pharmacokinet; 2001; 40(9):695-700. PubMed ID: 11605717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
    Jack C; Lalloo U; Karim QA; Karim SA; El-Sadr W; Cassol S; Friedland G
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):929-34. PubMed ID: 15220699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.